Theme II: new drugs Aldosterone: antagonists and cardiovascular protection.
نویسندگان
چکیده
منابع مشابه
Cardiovascular benefits of aldosterone receptor antagonists: what about potassium?
Before the mid-1990s, much data supported the hypothesis that the primary mechanism action of aldosterone was to maintain sodium, volume, and potassium homeostasis. This is accomplished by a direct effect on epithelial cells of the distal segments of the nephron to actively promote sodium transport out of and potassium transport into the tubular lumen. This primary mechanism of action was reinf...
متن کاملINIew Drugs Calcium antagonists , nitrates , and new antianginal drugs
Considerable progress in the medical as well as the surgical management of angina has been made in the past decade. An appreciation of the pharmacokinetics of the "oldest" antianginal drugs, the nitrates, has lead to the development of effective long acting preparations and novel techniques of administration. On the other hand, calcium antagonists represent a new approach to the treatment of an...
متن کاملAldosterone and aldosterone antagonists in cardiac disease: what is known, what is new.
Experimental and clinical studies indicate that exposure to high aldosterone concentrations causes cardiac damage independent of the blood pressure level. In recent years, it has become clear that the effects of aldosterone on the heart are mediated by actions on a variety of cell types and intracellular mechanisms that contribute to regulation of specific tissue responses, leading to hypertrop...
متن کاملAldosterone antagonists in hypertension and heart failure.
Spironolactone, a competitive aldosterone receptor antagonist (ARA), has traditionally been the treatment of first choice in idiopathic hyperaldosteronism (IHA) and for preoperative management of aldosterone producing adenoma (APA). Spironolactone is partially absorbed, is extensively metabolized mainly by the liver and its therapeutic properties are attributable to active metabolite canrenone....
متن کاملAldosterone receptor antagonists: current perspectives and therapies
Aldosterone is a downstream effector of angiotensin II in the renin-angiotensin-aldosterone system and binds to the mineralocorticoid receptor. The classical view of aldosterone primarily acting at the level of the kidneys to regulate plasma potassium and intravascular volume status is being supplemented by evidence of new "off-target" effects of aldosterone in other organ systems. The genomic ...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: American Journal of Hypertension
سال: 1999
ISSN: 0895-7061
DOI: 10.1016/s0895-7061(99)80767-5